Triple threat: new cell therapy combo targets advanced melanoma
NCT ID NCT06739226
First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 28 times
Summary
This study tests a combination of three immune-based treatments—CAR T cells, cytotoxic T lymphocytes (CTLs), and dendritic cell (DC) vaccines—in people with advanced melanoma that has not responded to standard therapy. The goal is to see if this approach is safe and can shrink tumors or slow disease progression. The trial enrolls 30 adults aged 18 to 75 with non-resectable, metastatic, or recurrent melanoma.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shenzhen Geno-Immune Medical Institute
RECRUITINGShenzhen, Guangdong, 518000, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.